The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2017 | How the AURA3 trial has changed conversations about re-biopsy in second-line lung cancer treatment
Neal Navani, MA, MBBS, MRCP, MSc, PhD, University College London, London, UK, discusses the risk-benefit of performing a re-biopsy in order to determine whether patients with progressive lung cancer can benefit from second-line treatment with EGFR inhibitors, such as osimertinib.
There was previously some reticence among oncologists to commit their patients to a second biopsy. However, following the results of the AURA3 trial, which demonstrated excellent progression-free survival with a second-line EGFR inhibitor, the risk-benefit is now in favour of a re-biopsy. Dr Navani adds that this is set to change the conversation that oncologists will have with their patients about re-biopsy, and requires a good understanding of biopsy techniques, associated risks and side effects.
Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
